全文获取类型
收费全文 | 7753篇 |
免费 | 677篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 51篇 |
儿科学 | 171篇 |
妇产科学 | 208篇 |
基础医学 | 1159篇 |
口腔科学 | 109篇 |
临床医学 | 1005篇 |
内科学 | 1544篇 |
皮肤病学 | 86篇 |
神经病学 | 611篇 |
特种医学 | 418篇 |
外科学 | 1027篇 |
综合类 | 210篇 |
一般理论 | 2篇 |
预防医学 | 881篇 |
眼科学 | 48篇 |
药学 | 543篇 |
中国医学 | 1篇 |
肿瘤学 | 375篇 |
出版年
2021年 | 100篇 |
2020年 | 79篇 |
2019年 | 102篇 |
2018年 | 125篇 |
2017年 | 117篇 |
2016年 | 84篇 |
2015年 | 115篇 |
2014年 | 165篇 |
2013年 | 250篇 |
2012年 | 373篇 |
2011年 | 408篇 |
2010年 | 206篇 |
2009年 | 174篇 |
2008年 | 348篇 |
2007年 | 306篇 |
2006年 | 316篇 |
2005年 | 290篇 |
2004年 | 336篇 |
2003年 | 321篇 |
2002年 | 280篇 |
2001年 | 302篇 |
2000年 | 276篇 |
1999年 | 256篇 |
1998年 | 99篇 |
1997年 | 94篇 |
1996年 | 94篇 |
1995年 | 91篇 |
1994年 | 86篇 |
1993年 | 71篇 |
1992年 | 207篇 |
1991年 | 200篇 |
1990年 | 212篇 |
1989年 | 165篇 |
1988年 | 153篇 |
1987年 | 141篇 |
1986年 | 150篇 |
1985年 | 139篇 |
1984年 | 116篇 |
1983年 | 91篇 |
1982年 | 68篇 |
1981年 | 53篇 |
1980年 | 46篇 |
1979年 | 81篇 |
1978年 | 62篇 |
1977年 | 49篇 |
1974年 | 68篇 |
1973年 | 48篇 |
1972年 | 46篇 |
1971年 | 45篇 |
1970年 | 52篇 |
排序方式: 共有8449条查询结果,搜索用时 0 毫秒
21.
Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators 总被引:3,自引:2,他引:1 下载免费PDF全文
T. van der Molen D. S. Postma M. O. Turner B. M. Jong J. L. Malo K. Chapman R. Grossman C. S. de Graaff R. A. Riemersma M. R. Sears 《Thorax》1997,52(6):535-539
BACKGROUND: The long acting beta 2 agonist formoterol has proved to be an effective bronchodilator with a prolonged action of 12-14 hours. However, the precise role of formoterol in the maintenance treatment of asthma is still under debate. A study was performed to investigate the efficacy and safety of treatment with formoterol for six months in subjects with asthma. METHODS: In a multicentre double blind, placebo controlled, parallel group study 239 subjects with mild to moderate asthma were randomly assigned to treatment with either inhaled formoterol 24 micrograms twice daily (n = 125) or placebo (n = 114) during eight months. The study consisted of a four week run in period, a 24 week treatment period, and a four week washout period. All subjects were using regular inhaled corticosteroids (100-3200 micrograms daily) but were still needing at least five inhalations of short acting beta 2 agonist per week for symptom relief. The study was performed in 10 outpatient clinics in Canada, and five outpatient clinics and one coordinating centre for 44 Dutch general practitioners in The Netherlands. Twice daily self-reported peak expiratory flow (PEF) measurements, symptom scores, and rescue beta 2 agonist use during the last 28 treatment days compared with baseline values were used as main outcome measures. Spirometric values were measured at entry, at the start of treatment, after four, 12 and 24 weeks of treatment, and after four weeks washout. RESULTS: One hundred and twenty five subjects received formoterol 24 micrograms twice daily via Turbohaler and 114 received placebo. Baseline FEV1 was 67.1% predicted and mean bronchodilator reversibility was 26%. The mean total asthma symptom score was 3.6 (maximum possible 21). A significant decrease in symptoms in favour of formoterol (difference from placebo -0.64, 95% CI -0.04 to -1.23, p = 0.04) was observed. Compared with placebo, morning PEF increased (difference from placebo 28 l/min, 95% CI 18.3 to 37.7, p = 0.0001) and the use of short acting beta 1 agonists decreased (daytime difference from placebo -1.1 inhalation, 95% CI -1.4 to -0.7, p = 0.0001) in the formoterol group. PEF returned to baseline following discontinuation of formoterol, as did asthma symptom scores. Thirty three patients treated with formoterol and 32 treated with placebo required treatment with prednisolone during the study (58 and 55 courses, respectively). CONCLUSIONS: Adding formoterol 24 micrograms twice daily by Turbohaler to inhaled corticosteroids was effective in improving symptom scores and morning PEF, and decreasing the use of rescue beta 2 agonists. There was no apparent loss of asthma control during 24 weeks of treatment with formoterol.
相似文献
相似文献
22.
23.
Duane C. Chapman 《Archives of environmental contamination and toxicology》1992,22(3):296-299
Young striped bass (Morone saxatilis) with uninflated gas bladders were less sensitive to selenate and more sensitive to selenite exposure than normally developing striped bass in 96-hour acute toxicity tests. Gas bladder inflation failure is a common problem in the culture of striped bass and some other species, and care should be taken to avoid the use of fish with uninflated gas bladders in research. 相似文献
24.
Twenty-nine females with metastatic or locally recurrent carcinoma of the breast were treated orally with 1 g of medroxyprogesterone acetate (MPA) daily. This was used as a second- or third-line treatment. Serum concentration of MPA was measured over a 28-day period. We have demonstrated a significantly greater area-under-the-concentration-time curve, peak, and steady-state MPA concentration for Provera at 100- and 200-mg tablets (Upjohn) than for Farlutal at 500-mg tablets (Farmitalia). Relative bioavailability of preparations should be considered when prescribing or assessing treatment results when MPA is used. 相似文献
25.
Serum concentrations of alkaline phosphatase isoenzymes and osteocalcin in normal pregnancy 总被引:4,自引:0,他引:4
A Rodin A Duncan H W Quartero G Pistofidis G Mashiter K Whitaker D Crook J C Stevenson M G Chapman I Fogelman 《The Journal of clinical endocrinology and metabolism》1989,68(6):1123-1127
We measured serum alkaline phosphatase isoenzymes and osteocalcin levels in 40 healthy women at 4-week intervals throughout uncomplicated pregnancies and 6 weeks after delivery in 17 women. Serum bone alkaline phosphatase was significantly higher in the third trimester than in early pregnancy (P less than 0.001), and this elevation was still apparent at the end of the puerperium, suggesting increased bone turnover. Serum osteocalcin was not detected (less than 0.2 micrograms/L) after the first trimester in the majority of women, and it reappeared within 48 h after delivery. The disappearance of osteocalcin after the first trimester and its rapid reappearance after delivery suggest placental clearance of this peptide. We conclude that serum osteocalcin measurements cannot be used as a marker of bone metabolism during pregnancy. 相似文献
26.
The effect of chemical shift on magnetic resonance (MR) imaging of the pituitary fossa was studied. Healthy volunteers underwent conventional MR imaging of the pituitary fossa and then imaging with the frequency-encoding gradient reversed or with the phase- and frequency-encoding gradients interchanged. Comparison of the image pairs in each subject showed that the thin, black stripe evident at the water-fat interface within the pituitary fossa was altered when the gradients were changed. Therefore, the low-intensity signal within the pituitary fossa is a chemical shift misregistration effect. 相似文献
27.
28.
29.
30.